Her blev MIRCERA givet subkutant hver anden uge i 28 uger og sammenlignet med darbepoetin alfa.
The second study, in 324 patients not on dialysis, looked at MIRCERA injected subcutaneously every two weeks over 28 weeks, comparing it with darbepoetin alfa.